SOURCE: Tufts Center for the Study of Drug Development

Tufts Center for the Study of Drug Development

November 10, 2014 09:00 ET

ADVISORY - Tufts CSDD to Disclose Cost of Developing a New Drug at Nov. 18 Briefing

BOSTON, MA--(Marketwired - Nov 10, 2014) -

Tufts Center for the Study of Drug Development, Tufts University, Boston, Mass.

Press briefing at which Tufts CSDD will present results of its latest study, updating the total average cost of developing a new prescription drug.

The Tufts CSDD estimate is the number that industry, governments, payers, and others depend on for strategic planning and formulation of prescription drug policy.

Invited to attend the briefing. Please register in advance by emailing

Tuesday, Nov. 18, 2014
10:00 - 11:00 a.m., Eastern time

Tufts University School of Medicine
Sackler School of Graduate Biomedical Sciences
145 Harrison Avenue, Sackler 114 East, First Floor, Boston

Nearest MBTA stop: Tufts Medical Center on the MBTA Orange line.

Parking available at Tufts Medical Center Garage at 274 Tremont Street, Boston, and Pilgrim Parking Corporation at 40 Beach Street, Boston.

The briefing will be webcast live. To access it, click on

What it costs to develop and win marketing approval for a new prescription drug is of strong and growing interest to a broad range of constituencies: drug developers and their research partners, investors, payers, legislators, patient advocacy groups, health care policy analysts/makers, academic researchers, and others working with the research-based biopharmaceutical industry and/or concerned with the economics of drug development.

The Tufts CSDD estimate is based on rigorous analysis of real-world data and is acknowledged to be the objective standard.

News release summarizing key findings will be made available at 10:30 a.m. on Nov. 18.

Dr. Joseph A. DiMasi, director of economic analysis at Tufts CSDD and principal investigator for the study.

Dr. Kenneth I Kaitin, director of Tufts CSDD.

Contact Information